Swiss drugmaker Novartis said the latest findings from a study on its newest therapy for two kinds of blood cancer track earlier results, bolstering its confidence in a 2017 U.S. regulatory submission.   Novartis is testing CTL019, its investigational chimeric antigen receptor T cell therapy, or CART, on 15 adult patients with the most-common non-Hodgkins […]

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which […]

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp’s Revlimid and common anti-inflammatory drug […]

New York and Zug, Switzerland-based Turing Pharmaceuticals LLC announced yesterday a 50 percent cut in its prices for toxoplasmosis drug Daraprim.   Turing and its controversial chief executive officer Martin Shkreli became the focus of a national discussion of drug pricing in August after it acquired Daraprim from IMPAX Laboratories, Inc. (IPKL) for $55 million. […]

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer. Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30. The drug has been approved for […]

Swiss drugmaker Roche released on Monday what it called encouraging early data on cancer drug atezolizumab in combination therapy for treating a form of advanced melanoma.   A phase Ib study of atezolizumab (MPDL3280A), used in combination with the BRAF inhibitor Zelboraf for previously untreated BRAFV600 mutation-positive inoperable or metastatic melanoma, showed adverse events were […]

New data from a midstage trial show that Celldex Therapeutics Inc’s experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer. The updated results sent shares of Celldex up $1.74, or 12 percent, to $16.23 on the Nasdaq. The therapy, designed to enlist the body’s immune […]

U.S. Food and Drug Administration staff reviewers said clinical data to date did not merit approving BioMarin Pharmaceutical Inc’s muscle-wasting disorder drug. The FDA staff reviewers raised questions over the clinical benefit of the drug, drisapersen, and said long-term data submitted by BioMarin did not support an approval at this time. BioMarin’s shares fell 8.7 […]

U.S. drugmaker Pfizer and France’s Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers. The so-called CAR T cell technology used by Cellectis involves reprogramming immune system cells to hunt out cancer. The “off-the-shelf” approach recently proved very successful in the case of a […]

U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. The U.S. Food and Drug Administration on Monday said it had approved Darzalex (daratumumab) for patients who had already undergone at least three prior standard […]